Table 1 Characteristics of reports on taxanes-associated dilis in the FAERS database (January 2004 to March 2024).

From: FAERS based disproportionality analysis and network pharmacology investigation of taxanes associated drug induced liver injury

 

Paclitaxel

Docetaxel

Nab-paclitaxel

Gender

 Female (%)

864 (72.24)

143 (60.08)

352 (47.96)

 Male (%)

219 (18.31)

84 (35.29)

251 (34.20)

 Unknown (%)

113 (9.45)

11 (4.62)

131 (17.85)

Age

 < 18 (%)

6 (0.50)

–

–

 18–65 (%)

643 (53.76)

122 (51.26)

294 (40.05)

 ≥ 65 (%)

328 (27.42)

74 (31.09)

247 (33.65)

 Unknown (%)

219 (18.31)

42 (17.65)

193 (26.29)

Reporter

 Physician (%)

480 (40.13)

94 (39.50)

285 (38.83)

 Pharmacist (%)

289 (24.16)

27 (11.34)

90 (12.26)

 Other health-professional (%)

283 (23.66)

69 (28.99)

304 (41.42)

 Consumer (%)

104 (8.70)

19 (7.98)

34 (4.63)

 Lawyer (%)

–

–

1 (0.14)

 Unknown (%)

40 (3.34)

29 (12.18)

20 (2.72)

Reported countries

 Germany

36 (3.01)

–

73 (9.95)

 Canada

22 (1.84)

15 (6.30)

58 (7.90)

 Australia

–

–

12 (1.50)

 Poland

20 (1.67)

–

–

 Finland

–

–

11 (1.50)

 Austria

14 (1.17)

–

–

 Egypt

11 (0.92)

–

–

 Belgium

10 (0.84)

–

–

 Portugal

9 (0.75)

–

–

 Slovenia

9 (0.75)

–

–

 France

201 (16.81)

14 (5.88)

26 (3.54)

 Italy

175 (14.63)

–

52 (7.08)

 USA

95 (7.94)

24 (10.08)

110 (14.99)

 Japan

91 (7.61)

14 (5.88)

123 (16.76)

 China

71 (5.94)

–

61 (8.31)

 Netherlands

70 (5.85)

–

–

 Spain

65 (5.43)

–

49 (6.68)

 UK

39 (3.26)

–

16 (2.18)

 Other

258 (21.57)

171 (71.85)

143 (19.48)

Time-to-onset (days)

 Median (q1, q3)

21.00 (7.00, 58.75)

11.00 (5.00, 29.00)

21.00 (7.00, 71.00)

Back to article page